Compare STGW & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STGW | AGIO |
|---|---|---|
| Founded | 1980 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2006 | 2013 |
| Metric | STGW | AGIO |
|---|---|---|
| Price | $6.44 | $28.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | $8.39 | ★ $38.88 |
| AVG Volume (30 Days) | ★ 1.5M | 686.7K |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,909,000,000.00 | $43,011,000.00 |
| Revenue This Year | $13.27 | $76.75 |
| Revenue Next Year | $4.07 | $170.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 2.39 | N/A |
| 52 Week Low | $4.28 | $22.24 |
| 52 Week High | $7.52 | $46.00 |
| Indicator | STGW | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 47.74 | 49.15 |
| Support Level | $4.94 | $26.75 |
| Resistance Level | $6.50 | $29.49 |
| Average True Range (ATR) | 0.35 | 1.30 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 31.60 | 44.13 |
Stagwell Inc is a challenger network using AI to deliver marketing and advertising solutions to its clients. It operates in five reportable segments: Marketing Services, Digital Transformation, Media and Commerce, Communications, and The Marketing Cloud. Maximum revenue is generated from the Marketing Services segment, which offers social media solutions, designs breakthrough brand campaigns, and creates immersive experiential marketing programs and social engagement strategies, helping clients connect with audiences across digital platforms. The various brands operating under this segment include 72 and Sunny, Anomaly, NRG, Harris Insights, TEAM, and Movers & Shaker. Geographically, the company generates maximum revenue from the United States, followed by the UK and other countries.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.